Osteogene Tech

What Osteogene Tech does

Osteogene Tech Corp is a privately held medical device company founded in July 2015 and headquartered in Norwood, New Jersey, where it also operates its in-house manufacturing facility. The company develops and sells InRoad®, a synthetic dental bone graft composed of approximately 90% hydroxyapatite and 10% β-tricalcium phosphate in a multi-porous, honeycomb-inspired trabecular structure. InRoad® is positioned for dental bone grafting procedures — including filling bony defects and voids and preparing implant sites — and is sold exclusively to qualified dental and medical professionals.

The underlying scaffold technology is licensed from the University of Texas (Patent US8916228B2 and related international filings) and is differentiated by a three-tier pore architecture (macro pores of 250-350μm, micro-channels of 50-79μm, and submicron pores) yielding porosity above 75% and approximately 28% greater surface area than single-porous alternatives. InRoad® received US FDA 510(k) clearance in March 2022 (No. K202675) and ISO 13485 certification in May 2023, and is offered in two granule sizes (0.3-1.0mm and 0.8-1.8mm) across four volume configurations (0.5cc, 1.0cc, 2.0cc, 3.0cc).

Osteogene Tech operates a direct-to-professional e-commerce model through a Shopify storefront that requires practitioner registration and license verification before purchase, supplemented by event-driven demand generation at major dental conferences (Academy of Osseointegration, American Academy of Periodontology, European Association for Osseointegration, IAOMT, CIOSP São Paulo). The company is led by Board Chairman and CEO Dongwoo Sohn, Ph.D., and Chief Science Officer and VP Daniel S. Oh, Ph.D. — a co-inventor of the licensed scaffold technology — with a 11-50 employee headcount and no disclosed external funding rounds or institutional investors in the available source material.

Name

Osteogene Tech

Legal name

Osteogene Tech Corp

Website

https://osteogene.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Osteogene Tech is a privately held medical device company that develops and sells InRoad®, a synthetic dental bone graft, exclusively to qualified dental professionals through a practitioner-verified e-commerce storefront and major dental conferences worldwide.

Ownership category

akta.pro rank

Headquarters

HQ city

Norwood

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. InRoad® Product Sales: Direct e-commerce sales of InRoad® Dental Synthetic Bone Graft through the company website. Products are sold in two sizes (0.3-1.0mm small and 0.8-1.8mm large) and four volume options (0.5cc, 1.0cc, 2.0cc, 3.0cc). Payment is collected via credit card at time of order. The product is intended for single use only and requires specialized dental/medical professionals to administer.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Osteogene Tech develops and manufactures InRoad®, a synthetic dental bone graft composed of 90% hydroxyapatite and 10% beta-tricalcium phosphate in a multi-porous, honeycomb-inspired trabecular structure. The product is sold to qualified dental and medical professionals for filling bony defects and voids in dental bone grafting and implant preparation procedures. Available in two granule sizes and four volume configurations, the single-use device is sterilized by gamma irradiation and distributed via the company's e-commerce storefront with professional registration verification.

Product overview

Osteogene Tech is a single-product medical device company focused on the InRoad® Dental Synthetic Bone Graft, a synthetic bone regeneration product for dental applications. The product is based on bioceramic technology combining hydroxyapatite and β-tricalcium phosphate in a multi-porous honeycomb-inspired structure. Originally developed with military trauma applications in mind, the technology was refined for dental bone grafting procedures and received FDA 510(k) clearance in March 2022. The company operates from its manufacturing facility in Norwood, NJ.

Differentiator

Problem solved

Functional benefit

Brands

• InRoad: Dental Synthetic Bone Graft - osteoconductive, bioceramic bone graft composed of 90% hydroxyapatite and 10% beta-tricalcium phosphate with multi-porous structure.

Products and services

• InRoad® Dental Synthetic Bone Graft An osteoconductive, bioceramic synthetic bone graft composed of 90% hydroxyapatite and 10% beta-tricalcium phosphate with a semi-dense, multi-porous, trabecular-like structure. Available in two granule sizes (0.3-1.0mm small and 0.8-1.8mm large) and four volumes (0.5cc, 1.0cc, 2.0cc, 3.0cc). Sterilized via gamma irradiation, single-use, and intended for filling bony defects and voids in dental bone grafting procedures. Sold exclusively to qualified dental professionals.

Quantifiable outcome

• Porosity greater than 75%
• +4 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core, notable and minor.

• University of TexascoreTechnology or Integration · 1 September 2015License agreement obtained in September 2015 for Bi-Layered Bone-like Scaffold technology invented by Dr. Danial S. Oh and Dr. Joo Ong. This forms the foundational technology for InRoad® product development.
• Columbia UniversitynotableStrategic or Co-development PartnerListed as a partner organization, suggesting collaborative research or academic relationship in bone regeneration science.
• U.S. Department of DefensenotableStrategic or Co-development PartnerPartner organization. Company history indicates initial research was directed toward military personnel injured in the line of duty, suggesting ongoing military medical applications research.
• Veterans Affairs (VA)notableStrategic or Co-development PartnerListed as a partner organization, indicating collaboration in veteran healthcare applications.
• Edel WeissminorOthersListed as a partner organization on the company website.
• KairosminorOthersListed as a partner organization on the company website.
• OCGminorOthersListed as a partner organization on the company website.
• Chonnam National UniversitynotableStrategic or Co-development PartnerListed as a partner organization, indicating academic research collaboration.
• Ettore Marini, DMDcoreStrategic or Co-development PartnerChairman of Medical Advisory Committee. Conducted workshop and hands-on training for InRoad® synthetic bone graft with Dr. Daniel Oh in Italy.
• Antonello Maria Messina, DMDcoreStrategic or Co-development PartnerVice Chair of Medical Advisory Committee. Collaborated on hands-on training sessions for InRoad® synthetic bone graft.

Scale indicators3 records

Recent moves10 records

Expansion highlights4 records

Direct peers

• Botiss Biomaterials: Botiss is a European dental regenerative company offering bone graft substitutes (e.g., cerabone, maxgraft), barrier membranes, and soft tissue products. It directly competes with InRoad® in dental bone regeneration procedures across European markets where Osteogene is also active.
• Geistlich Pharma: Geistlich is the dominant player in dental bone regeneration with Bio-Oss (xenograft) and Bio-Gide, the de-facto standard products used in dental implant and bone grafting procedures worldwide — directly comparable to Osteogene's InRoad® in target use case (dental bone void filling) and end customer (dental specialists).
• ZimVie (Zimmer Biomet Dental): ZimVie offers RegenerOss and other dental bone graft and membrane products used by periodontists and oral surgeons. It is a direct competitor in the dental synthetic and allograft bone graft market serving the same clinician base as Osteogene Tech.
• RTI Surgical: RTI Surgical (now with the Stereotaxis spinoff context and ongoing biologics business) develops bone graft substitutes and synthetic bone repair products serving dental and orthopedic markets. It is a comparable synthetic bone graft manufacturer to Osteogene Tech in technology platform and end-user markets.
• NovaBone Products: NovaBone manufactures synthetic calcium-phosphate bone graft products (including dental putty formulations) targeting dental and orthopedic bone regeneration. It is one of the closest synthetic-bone-graft head-to-head competitors to Osteogene Tech in technology approach and clinical application.
• LifeNet Health: LifeNet Health provides allograft dental bone grafting products (e.g., cancellous/cortical particulate, regenerative tissue matrices) used by periodontists and oral surgeons. It competes in the dental bone void-filling market served by InRoad®, although with a biological rather than synthetic product.

Broad incumbents

• BioHorizons (Henry Schein): BioHorizons, now part of Henry Schein, manufactures dental implants and regenerative products (allograft particulate, xenograft, membranes) sold to periodontists and oral surgeons. Its dental regenerative biomaterials line competes with InRoad® in the same surgical workflows.
• Dentsply Sirona: Dentsply Sirona is a broad dental equipment and consumables manufacturer offering regenerative solutions (e.g., Symbios allograft, bone graft putties) alongside implants, instruments, and chairside systems. Its regenerative portfolio overlaps with Osteogene's dental bone graft offering to specialist clinicians.
• Straumann Group: Straumann is a global leader in dental implants and offers a portfolio of biomaterials (XenoFlex, cerabone, etc.) used in dental bone regeneration. While broader than Osteogene (implants, prosthetics, digital dentistry), its regenerative biomaterials line directly overlaps with InRoad®'s dental bone grafting use case.
• Septodont: Septodont is a global dental pharmaceutical and consumables company with bone graft substitute offerings (e.g., R.T.R. cone/granules) used in dental bone regeneration procedures. Its established dental distribution network and broad product portfolio make it an incumbent comparable to Osteogene's specialized play.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/osteogene-tech-corp
• Instagraminstagram.com/osteogenetech

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osteogene Tech